Evidence map›Paper›PMID 22952217›Full record

ArticleCancer research2012

A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model.

Bartley J Gill, Don L Gibbons, Laila C Roudsari, Jennifer E Saik, Zain H Rizvi, Jonathon D Roybal, Jonathan M Kurie, Jennifer L West

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 168 citations in OpenAlex.

  1. Trial
  2. Biomimetic Scaffold-Based 3D Models for Decoding Cancer Biology and Advancing Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Making In Vitro Tumor Models Whole Again.Advanced healthcare materials · 2023
    Review
  19. Review
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Bartley J GillDepartment of Bioengineering, Rice University, Houston, Texas 77005, USA.
Don L Gibbons
Laila C Roudsari
Jennifer E Saik
Zain H Rizvi
Jonathon D Roybal
Jonathan M Kurie
Jennifer L West
The University of Texas MD Anderson Cancer Center · USRice University · US

Funding

UNIVERSITY OF TEXAS--SPORE IN LUNG CANCERP50CA070907 · NCI · UT SOUTHWESTERN MEDICAL CENTER · PI HEYMACH, JOHN V. · 1996 to 2024
$57.4M
BIOTECHNOLOGY RESEARCH TRAINING GRANTT32GM008362 · NIGMS · RICE UNIVERSITY · PI WEST, JENNIFER L · 1990 to 2010
$3.6M
Regulation of Lung Cancer Metastasis by miR-200R01CA157450 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KURIE, JONATHAN M · 2011 to 2015
$1.6M
MicroRNA-200 family regulation by the apical-basal polarity complexes in EMT andK08CA151651 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI GIBBONS, DON LYNN · 2010 to 2014
$853k
Howard Hughes Medical InstituteNCI NIH HHS K08 CA151651NCI NIH HHS NCI K08 CA151651NCI NIH HHS NIH R01 CA157450NCI NIH HHS P50 CA070907NCI NIH HHS P50 CA70907NCI NIH HHS R01 CA157450NIGMS NIH HHS 5T32 GM008362-19NIGMS NIH HHS T32 GM008362
6 · The paper itself

Abstract

Better understanding of the biophysical and biochemical cues of the tumor extracellular matrix environment that influence metastasis may have important implications for new cancer therapeutics. Initial exploration into this question has used naturally derived protein matrices that suffer from variability, poor control over matrix biochemistry, and inability to modify the matrix biochemistry and mechanics. Here, we report the use of a synthetic polymer-based scaffold composed primarily of poly(ethylene glycol), or PEG, modified with bioactive peptides to study murine models of lung adenocarcinoma. In this study, we focus on matrix-derived influences on epithelial morphogenesis of a metastatic cell line (344SQ) that harbors mutations in Kras and p53 (trp53) and is prone to a microRNA-200 (miR-200)-dependent epithelial-mesenchymal transition (EMT) and metastasis. The modified PEG hydrogels feature biospecific cell adhesion and cell-mediated proteolytic degradation with independently adjustable matrix stiffness. 344SQ encapsulated in bioactive peptide-modified, matrix metalloproteinase-degradable PEG hydrogels formed lumenized epithelial spheres comparable to that seen with three-dimensional culture in Matrigel. Altering both matrix stiffness and the concentration of cell-adhesive ligand significantly influenced epithelial morphogenesis as manifest by differences in the extent of lumenization, in patterns of intrasphere apoptosis and proliferation, and in expression of epithelial polarity markers. Regardless of matrix composition, exposure to TGF-β induced a loss of epithelial morphologic features, shift in expression of EMT marker genes, and decrease in mir-200 levels consistent with EMT. Our findings help illuminate matrix-derived cues that influence epithelial morphogenesis and highlight the potential utility that this synthetic matrix-mimetic tool has for cancer biology.

Indexed as

Epithelial-Mesenchymal TransitionAdenocarcinomaAdenocarcinoma of LungAnimalsCell Culture TechniquesCell Line, TumorDisease Models, AnimalEpithelial CellsExtracellular MatrixGenes, p53Genes, rasHydrogelsLung NeoplasmsMiceMutationOligopeptidesarginyl-glycyl-aspartyl-serineHydrogelsOligopeptidesPolyethylene Glycols

Identifiers

PMID22952217
PMCPMC3632398
OpenAlexW2156174107

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.